摘要
目的分析急性淋巴细胞白血病(ALL)患儿经华南地区儿童急性淋巴细胞白血病治疗协作组2016方案(SCCLG-2016)治疗后复发的相关因素。方法选择2016年8月至2017年8月深圳市儿童医院血液肿瘤科收治ALL患儿364例为研究对象,分析364例接受SCCLG-2016方案治疗的结果,随访复发情况和相关病理资料,采用Logistics回归分析影响其治疗后复发的独立危险因素。结果 364例ALL患儿复发率为18.68%(68/364),复发组与未复发组患儿年龄、白细胞数目、融合基因阳性率、微小残留病变及危险度分级比较差异均有统计学意义(P<0.05),其中年龄≥10岁、白细胞数目≥100×10~9/L和BCR/ABL基因阳性、危险分级为高危者是影响ALL患儿治疗后复发的独立危险因素。结论年龄≥10岁、白细胞数目≥100×10~9/L及融合基因阳性、危险分级为高危是ALL患儿经SCCLG-2016方案治疗后复发的独立危险因素,治疗时密切关注以上因素,有利于识别复发概率较高者,早期干预。
Objective To analyze the related factors for recurrence acute lymphoblastic leukemia(ALL)in child patients after treatment with 2016 regimen of South China Children's Acute Lymphocytic Leukemia Treatment Cooperative Group(SCCLG-2016).Methods Totally 364 child patients with ALL who underwent SCCLG-2016 regimen in Department of Hematology and Oncology of Shenzhen Children's Hospital were selected for the study.The treatment results of 364 patients who underwent SCCLG-2016 regimen were analyzed,and the recurrence and related pathological data were followed up.Logistics regression analysis was used to analyze the independent risk factors affecting recurrence after treatment.Results The recurrence rate was18.68%(68/364)in 364 children patients with ALL,and there were significant differences in the age,white blood cell count,fusion gene positive rate,minimal residual disease and risk grading between recurrence group and no-recurrence group(P<0.05).The age≥10years old,white blood cell count≥100×10^9/L and positive BCR/ABL gene and high risk grade were independent risk factors for recurrence in child patients with ALL after treatment.Conclusion Age≥10years old,white blood cell count≥100×10^9/L,positive fusion gene and high risk grade are independent risk factors for recurrence in child patients with ALL after SCCLG-2016regimen.Paying close attention to the above factors during treatment is helpful to identify the patients with higher probability of recurrence so as to give early intervention.
作者
刘仕林
文飞球
刘四喜
李长钢
LIU Shilin;WEN Feiqiu;LIU Sixi;LI Changgang(Departmentof Hematology and Oncology,Shenzhen Children's Hospital,Shenzhen 518038,China)
出处
《中国中西医结合儿科学》
2018年第6期528-531,共4页
Chinese Pediatrics of Integrated Traditional and Western Medicine
基金
深圳市科创委项目(JCYJ20150403100317054)
